ClinicalTrials.gg
CompletedNCT00338650Updated Nov 29, 2007

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

A Phase 3 interventional study of adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 97 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-11-29.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
Largest of 42
1,000 · median 143
Started
2006
with 2 others
Phase 3
22 of 42
none open now
Registered
6th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one has the largest enrollment, is one of 3 that started in 2006, is one of 22 in phase 3, and was the 6th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient diagnosed with moderate to severe Crohn's Disease.
  • Failed prior infliximab therapy.
  • Patient is judged to be in generally good health as determined by the principal investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with adalimumab.
  • Patient considered by the investigator, for any reason, to be an unsuitable candidate
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. AEs, laboratory data, physical examinations and vital signs

Secondary outcomes

  1. Efficacy variables will be assessed from Outcomes Questionnaires

07

Study locations

97 sites
  • Birmingham, Alabama 35209, United States
  • Jonesboro, Arkansas 72401, United States
  • Little Rock, Arkansas 72205, United States
  • Roseville, California 95661, United States
  • San Francisco, California 94115, United States
  • Englewood, Colorado 80113, United States
  • Wheat Ridge, Colorado 80033, United States
  • Bridgeport, Connecticut 06606, United States
  • Hamden, Connecticut 06518, United States
  • Clearwater, Florida 33765, United States
  • Gainesville, Florida 32607, United States
  • Gainesville, Florida 32610, United States
  • Hollywood, Florida 33021, United States
  • Jacksonville, Florida 32224, United States
  • Jacksonville, Florida 32256, United States
  • Miami, Florida 33173, United States
  • North Miami Beach, Florida 33162, United States
  • Winter Park, Florida 32789, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30309, United States
  • Atlanta, Georgia 30342, United States
  • Conyers, Georgia 30012, United States
  • Marietta, Georgia 30060, United States
  • Savannah, Georgia 31405, United States
  • Arlington Heights, Illinois 60005, United States
  • Moline, Illinois 61265, United States
  • Rockford, Illinois 61107, United States
  • Columbus, Indiana 47201, United States
  • Indianapolis, Indiana 46202-5250, United States
  • Indianapolis, Indiana 46237, United States
  • Clive, Iowa 50325, United States
  • Davenport, Iowa 52807, United States
  • Overland Park, Kansas 66212, United States
  • Topeka, Kansas 66606, United States
  • Lexington, Kentucky 40536, United States
  • Annapolis, Maryland 21401, United States
  • Chevy Chase, Maryland 20815, United States
  • Lutherville, Maryland 21093, United States
  • Silver Spring, Maryland 20901, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02118, United States
  • Burlington, Massachusetts 01805, United States
  • Troy, Michigan 48098, United States
  • Plymouth, Minnesota 55446, United States
  • Picayune, Mississippi 39466, United States
  • Kansas City, Missouri 64131, United States
  • Mexico, Missouri 65265-3726, United States
  • St. Louis, Missouri 63128, United States
  • Lebanon, New Hampshire 03756, United States
  • Egg Harbor Township, New Jersey 08234, United States
  • Glen Ridge, New Jersey 07028, United States
  • Manalapan, New Jersey 07726, United States
  • Great Neck, New York 11021, United States
  • Lake Success, New York 11042, United States
  • New York, New York 10021, United States
  • New York, New York 10022, United States
  • New York, New York 10028, United States
  • New York, New York 10128, United States
  • Rochester, New York 14607, United States
  • Charlotte, North Carolina 28207, United States
  • Charlotte, North Carolina 28211, United States
  • Jacksonville, North Carolina 28546, United States
  • Rocky Mount, North Carolina 27804, United States
  • Wilmington, North Carolina 28401, United States
  • Wilmington, North Carolina 28403, United States
  • Beachwood, Ohio 44122, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45220, United States
  • Cincinnati, Ohio 45242, United States
  • Cleveland, Ohio 44195, United States
  • Warren, Ohio 44484, United States
  • Tulsa, Oklahoma 74104, United States
  • Tulsa, Oklahoma 74135, United States
  • Portland, Oregon 97220, United States
  • Portland, Oregon 97225, United States
  • Beaver Falls, Pennsylvania 15010, United States
  • Duncansville, Pennsylvania 16635, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Pittsburgh, Pennsylvania 15232, United States
  • Pittsburgh, Pennsylvania 15243, United States
  • Sayre, Pennsylvania 18840, United States
  • Columbia, South Carolina 29204, United States
  • Chattanooga, Tennessee 37403, United States
  • Chattanooga, Tennessee 37404, United States
  • Germantown, Tennessee 38138, United States
  • Austin, Texas 78745, United States
  • South Ogden, Utah 84405, United States
  • Norfolk, Virginia 23502, United States
  • Bellevue, Washington 98004, United States
  • Seattle, Washington 98101, United States
  • Spokane, Washington 99204, United States
  • Vancouver, Washington 98664, United States
  • Milwaukee, Wisconsin 53215, United States
  • Milwaukee, Wisconsin 53226, United States
  • Milwaukee, Wisconsin 53233, United States
  • Monroe, Wisconsin 53566, United States
08

References and documents

Publications

  • Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28. PubMed 20955442 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2006
First posted
Jun 20, 2006
Start
Jun 2006
CompletionActual
May 2007
Last update
Nov 29, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00338650
Lead sponsor
Abbott
First posted
Jun 20, 2006
Start date
Jun 2006
Completion
May 2007
Last update
Nov 29, 2007

Study contacts

Beverly Paperiello
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion